Investigation Launches Into Alleged Securities Fraud by Encompass Health Corporation

Pomerantz Law Firm Investigates Encompass Health Corporation

In a recent development in the financial and healthcare sectors, Pomerantz LLP has initiated an investigation aimed at protecting investors of Encompass Health Corporation (NYSE: EHC). This inquiry arises in light of serious allegations suggesting that Encompass may have engaged in securities fraud and other potentially unlawful business practices.

The situation came to public attention following a report published by The New York Times on July 15, 2025, which claimed that hospitals operated by Encompass Health had consistently performed below average in key safety metrics. According to the article, it highlighted that many of the company's rehabilitation facilities were associated with unacceptably high rates of preventable readmissions to general hospitals – a troubling indication of the quality of care provided. Specifically, the report mentioned that Medicare had statistically rated 34 Encompass facilities as having significantly worse rates of potentially preventable hospital readmissions.

The timing of this report coincided with a sharp decline in Encompass’s stock performance, which plummeted by 10.35%, translating to a loss of $12.39 per share, closing at $107.28 on the same day. This financial setback has prompted affected investors to reach out to Pomerantz LLP for consultation about their legal options moving forward.

Pomerantz LLP has gained a reputation as one of the foremost firms specializing in corporate and securities class actions. With offices situated in major global cities, including New York, Chicago, London, and Tel Aviv, the firm has a longstanding history of advocating for the rights of investors. Since its inception, Pomerantz has been a pioneer in ensuring accountability for securities fraud and corporate misconduct.

Founded by Abraham L. Pomerantz, who was known as the 'dean of the class action bar,' the firm has recovered millions in damages for the victims of fraudulent practices. Over its85-year history, Pomerantz has continuously sought to uphold the principles of justice and fairness in the corporate realm. As the current investigation into Encompass Health unfolds, it highlights the ongoing struggle investors face in navigating the complexities of stock market investments, especially within industries as critical as healthcare.

For investors impacted by the decline in stock value, reaching out for support can be crucial. Danielle Peyton, an attorney with Pomerantz, has urged those who believe they have been affected to contact the firm for more information about joining the class action initiative. Interested parties can connect via email at [email protected] or call directly at 646-581-9980, ext. 7980.

The allegations against Encompass Health Corporation not only spotlight concerns regarding securities fraud but also raise broader questions about quality standards in healthcare. This situation could serve as a reference point for future considerations regarding accountability within the for-profit health sector, ensuring that patient safety remains a priority amid corporate interests.

As this investigation evolves, stakeholders from multiple angles—including investors, healthcare professionals, and regulatory bodies—will be keenly watching for further developments. This case serves as a reminder of the intricate interplay between corporate practices and investor confidence, as well as the fundamental importance of transparency and ethical accountability in healthcare operations.

For more updates about this investigation, stay tuned to our coverage as the story unfolds.